The estimated Net Worth of Robert J Gould is at least $9.23 Milión dollars as of 13 January 2023. Robert Gould owns over 6,766 units of Fulcrum Therapeutics Inc stock worth over $4,423,796 and over the last 11 years he sold FULC stock worth over $914,086. In addition, he makes $3,889,350 as President, Chief Executive Officer a Director at Fulcrum Therapeutics Inc.
Robert has made over 31 trades of the Fulcrum Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 6,766 units of FULC stock worth $101,490 on 13 January 2023.
The largest trade he's ever made was exercising 94,251 units of Fulcrum Therapeutics Inc stock on 1 April 2022 worth over $738,928. On average, Robert trades about 21,475 units every 85 days since 2014. As of 13 January 2023 he still owns at least 499,864 units of Fulcrum Therapeutics Inc stock.
You can see the complete history of Robert Gould stock trades at the bottom of the page.
Dr. Robert J. Gould Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Gould has served as our president and chief executive officer and as a member of our board of directors since July 2016. Dr. Gould previously served as president and chief executive officer of Epizyme, Inc., or Epizyme, a biopharmaceutical company, from March 2010 to September 2015. Prior to joining Epizyme, he served as director of novel therapeutics at the Broad Institute of Massachusetts Institute of Technology, or MIT, and Harvard, a research institute, from December 2006 to March 2010. Dr. Gould spent 23 years at Merck Research Laboratories, or Merck, a healthcare company, where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. Dr. Gould received a B.A. from Spring Arbor University and a Ph.D. from the University of Iowa and completed postdoctoral studies at the Johns Hopkins University. Gould’s extensive leadership experience in the life sciences industry and his extensive knowledge of our company based on his current role as our chief executive officer qualify him to serve on our board of directors.
As the President, Chief Executive Officer a Director of Fulcrum Therapeutics Inc, the total compensation of Robert Gould at Fulcrum Therapeutics Inc is $3,889,350. There are no executives at Fulcrum Therapeutics Inc getting paid more.
Robert Gould is 65, he's been the President, Chief Executive Officer a Director of Fulcrum Therapeutics Inc since 2016. There are 3 older and 10 younger executives at Fulcrum Therapeutics Inc. The oldest executive at Fulcrum Therapeutics Inc is Mark J. Levin, 71, who is the Exec. Chairman.
Robert's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk a Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include: